New hope for kids with Tough-to-Treat cancers
NCT ID NCT04928677
Summary
This study is testing whether codrituzumab is safe for children and young adults with solid tumors that have returned or stopped responding to standard treatments. Researchers will give the drug to up to 50 patients aged 1-21 years to check for side effects and see how the body processes it. The treatment targets tumors that produce a specific protein called GPC3.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY EXTRA-CRANIAL SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Healthcare of Atlanta (Data Collection Only)
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Children's Hospital of Los Angeles (Data Collection Only)
RECRUITINGLos Angeles, California, 90027, United States
Contact Phone: •••-•••-••••
-
Cincinnati Children's Hospital Medical Center
RECRUITINGCincinnati, Ohio, 45229, United States
Contact Phone: •••-•••-••••
-
Dana Farber Cancer Institute (Data Collection Only)
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.